0001209191-20-064020.txt : 20201217 0001209191-20-064020.hdr.sgml : 20201217 20201217160108 ACCESSION NUMBER: 0001209191-20-064020 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201215 FILED AS OF DATE: 20201217 DATE AS OF CHANGE: 20201217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: O'Connell Joseph P CENTRAL INDEX KEY: 0001723966 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38318 FILM NUMBER: 201396063 MAIL ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE STREET 2: SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Odonate Therapeutics, Inc. CENTRAL INDEX KEY: 0001717452 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822493065 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE STREET 2: SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-200-3830 MAIL ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE STREET 2: SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Odonate Therapeutics, Inc DATE OF NAME CHANGE: 20171207 FORMER COMPANY: FORMER CONFORMED NAME: Odonate Therapeutics, LLC DATE OF NAME CHANGE: 20170919 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-15 0 0001717452 Odonate Therapeutics, Inc. ODT 0001723966 O'Connell Joseph P C/O ODONATE THERAPEUTICS, INC. 4747 EXECUTIVE DRIVE, SUITE 210 SAN DIEGO CA 92121 0 1 0 0 Chief Medical Officer Common Stock 2020-12-15 4 A 0 121 12.91 A 3000 D Employee Stock Option (Right to Buy) 15.19 2020-12-15 4 A 0 121 0.00 A 2030-12-15 Common Stock 121 121 D These shares were acquired on 12/15/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. /s/ Michael Hearne, as attorney-in-fact for Joseph O'Connell 2020-12-17